We are live on ! Find out more
SFM

Sphera Funds Management Portfolio holdings

AUM $630M
1-Year Est. Return 108.65%
This Fund
S&P 500
This Quarter Est. Return
-4.24%
1 Year Est. Return
+108.65%
3 Year Est. Return
+217.64%
5 Year Est. Return
+342.91%
10 Year Est. Return
+2,254.45%
AUM
$733M
AUM Growth
+$21.5M
Cap. Flow
+$93.1M
Cap. Flow %
12.7%
Top 10 Hldgs %
32.84%
Holding
138
New
34
Increased
32
Reduced
32
Closed
20

Top Buys

Rank Stock Value
1
AVGO icon
Broadcom
AVGO
+$25.7M
2
SKYE icon
Skye Bioscience
SKYE
+$15.4M
3
ASML icon
ASML
ASML
+$9.52M
4
CRM icon
Salesforce
CRM
+$8.99M
5
BBIO icon
BridgeBio Pharma
BBIO
+$8.86M

Top Sells

Rank Stock Value
1
TEVA icon
Teva Pharmaceuticals
TEVA
+$16.9M
2
FUSN
Fusion Pharmaceuticals Inc. Common Shares
FUSN
+$9.57M
3
CAMT icon
Camtek
CAMT
+$6.97M
4
CATX icon
Perspective Therapeutics
CATX
+$6.61M
5
NVMI
Nova
NVMI
+$6.23M

Sector Composition

Rank Sector Weight
1 Healthcare 59.43%
2 Technology 17.13%
3 Communication Services 3.05%
4 Consumer Discretionary 3%
5 Utilities 0.37%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
KLAC icon
76
KLA
KLAC
$239B
$2.72M 0.37%
+33,000
New +$2.44M
SWTX
77
DELISTED
SpringWorks Therapeutics
SWTX
$2.65M 0.36%
70,269
– –
IRON icon
78
Disc Medicine
IRON
$2.96B
$2.62M 0.36%
58,044
+9,158
+19% +$311K
CRGX
79
DELISTED
CARGO Therapeutics
CRGX
$2.55M 0.35%
155,506
+80,506
+107% +$1.53M
PFE icon
80
Pfizer
PFE
$143B
$2.52M 0.34%
90,000
– –
NVDA icon
81
NVIDIA
NVDA
$4.86T
$2.47M 0.34%
+20,000
New +$2.02M
GLBE icon
82
Global E Online
GLBE
$6.6B
$2.43M 0.33%
66,884
-141,900
-68% -$4.58M
SRPT icon
83
CALL
Sarepta Therapeutics
SRPT
$1.57B
$2.37M 0.32%
+15,000
New +$1.93M
VTYX
84
DELISTED
Ventyx Biosciences
VTYX
$2.34M 0.32%
1,012,749
+20,000
+2% +$83.1K
TBLA icon
85
Taboola.com
TBLA
$1.37B
$2.3M 0.31%
667,384
-523,686
-44% -$2.11M
LRMR icon
86
Larimar Therapeutics
LRMR
$397M
$2.27M 0.31%
+312,469
New +$2.39M
LHX icon
87
L3Harris
LHX
$51.6B
$2.25M 0.31%
+10,000
New +$2.16M
ADCT icon
88
ADC Therapeutics
ADCT
$134M
$2.17M 0.3%
+685,547
New +$2.72M
NTR icon
89
Nutrien
NTR
$33.2B
$2.07M 0.28%
40,730
+5,000
+14% +$274K
PERI icon
90
Perion Network
PERI
$375M
$1.96M 0.27%
+234,609
New +$2.85M
KYTX icon
91
Kyverna Therapeutics
KYTX
$444M
$1.77M 0.24%
+236,029
New +$3.61M
ALMS
92
Alumis Inc
ALMS
$3.6B
$1.66M 0.23%
+125,000
New +$1.66M
CLYM
93
Climb Bio
CLYM
$681M
$1.53M 0.21%
+215,179
New +$1.43M
HOWL icon
94
Werewolf Therapeutics
HOWL
$17.2M
$1.53M 0.21%
626,810
– –
ATXS
95
DELISTED
Astria Therapeutics
ATXS
$1.48M 0.2%
162,842
+50,000
+44% +$488K
VIR icon
96
Vir Biotechnology
VIR
$1.46B
$1.44M 0.2%
+162,051
New +$1.55M
GLUE icon
97
Monte Rosa Therapeutics
GLUE
$1.4B
$1.4M 0.19%
+375,000
New +$1.91M
MRVL icon
98
Marvell Technology
MRVL
$168B
$1.4M 0.19%
+20,000
New +$1.4M
UPWK icon
99
Upwork
UPWK
$1.13B
$1.26M 0.17%
117,000
– –
ARWR icon
100
Arrowhead Research
ARWR
$11.9B
$1.25M 0.17%
+48,175
New +$1.18M
2 3
4
5 6

Similar funds

VIM
Vancity Investment Management Vancouver, British Columbia, Canada $629M AUM 2.49% 1-Year Est. Return
KCMH
Keywise Capital Management (HK) Hong Kong $630M AUM 81.01% 1-Year Est. Return
FCFC
First Commonwealth Financial Corp Indiana, Pennsylvania $629M AUM 20.47% 1-Year Est. Return
BI
BlueSpruce Investments Chicago, Illinois $631M AUM 11.83% 1-Year Est. Return
PWW
Pettyjohn Wood & White Lynchburg, Virginia $628M AUM 20.96% 1-Year Est. Return
TTSTC
Texas Treasury Safekeeping Trust Company Austin, Texas $628M AUM 15.58% 1-Year Est. Return
SWP
Summit Wealth Partners Orlando, Florida $632M AUM 9.71% 1-Year Est. Return
EIM
Essex Investment Management Boston, Massachusetts $632M AUM 95.36% 1-Year Est. Return

Sphera Funds Management's Q2 2024 Portfolio in Review

As of Q2 2024, Sphera Funds Management held 138 positions worth $733M, up 3% from $712M the previous quarter. Its ten largest holdings account for 33% of the portfolio.

Sphera Funds Management deployed $93.1M of net new capital in Q2 2024, opening 34 new positions and adding to 32 existing holdings. Its largest new stake was Skye Bioscience: 1,298,312 shares worth $10.4M.

By sector, the portfolio is most concentrated in Healthcare at 59% of assets, down from 65% a quarter earlier, followed by Technology and Communication Services.

On the sell side, the largest reduction was Teva Pharmaceuticals, an estimated $16.9M trimmed.

  • Sphera Funds Management's largest Q2 2024 buy was Skye Bioscience: 1,298,312 shares worth $10.4M.
  • Sphera Funds Management added most to Broadcom in Q2 2024, an estimated $25.7M increase.
  • Sphera Funds Management's biggest Q2 2024 reduction was Teva Pharmaceuticals, cutting an estimated $16.9M.
  • Sphera Funds Management fully exited Fusion Pharmaceuticals Inc. Common Shares in Q2 2024, selling an estimated $9.57M.
  • Sphera Funds Management's ten largest holdings make up 33% of its $733M portfolio in Q2 2024.
  • Sphera Funds Management opened 34 new positions and closed 20 in Q2 2024.
  • Sphera Funds Management's portfolio value rose 3% quarter-over-quarter to $733M.

Based on Sphera Funds Management's 13F filing for Q2 2024, filed 14 Aug 2024.